Immunological bases of increased susceptibility to invasive nontyphoidal Salmonella infection in children with malaria and anaemia.
Tonney S Nyirenda, Wilson L Mandala, Melita A Gordon...
https://pubmed.ncbi.nlm.nih.gov/29248635/Actively Recruiting
Led by International Vaccine Institute · Updated on 2026-02-18
10000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying children under the age of 5 living in the Kisantu Health Zone of the Democratic Republic of Congo to understand how malaria vaccination affects the risk of invasive non-typhoidal Salmonella iNTS disease. This observational study aims to compare the malaria vaccination status of children with and without iNTS infection to see if the malaria vaccine offers protection against this serious bacterial infection. The study uses a case-control design to analyze these relationships. The intervention under study is the R21Matrix-M malaria vaccine, which was introduced in the Expanded Program on Immunizations on October 29, 2024. Children between 6 and 24 months old are eligible for vaccination, which includes four doses the first dose between 6 and 11 months of age, followed by a second dose one month later, a third dose one month after that, and a booster dose seven months after the third dose. Participants are grouped based on their vaccination status, including those who received all four doses, partial doses, or no vaccination. Participants presenting with fever at healthcare facilities are tested for malaria and iNTS using blood cultures, microscopic blood smears, rapid diagnostic tests, and PCR for confirmation. Those diagnosed with iNTS andor malaria receive treatment according to national guidelines and are monitored until recovery or up to 21 days after enrollment. The study measures include confirmed iNTS infection rates in vaccinated versus unvaccinated children and the severity of infections. Follow-up assessments track disease outcomes and resolution of symptoms.
CONDITIONS
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
B
Birkneh Tadesse, MD, PHD
C
Camille Dauvergne, PharmD, M.S.c
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
International Vaccine Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) at healthcare facility when presenting with fever
Duration - Up to 2 years
Participants who present with fever are observed through febrile illness surveillance including malaria vaccination status verification and diagnostic testing for invasive non-typhoidal Salmonella (iNTS) and malaria.
Visits occur when participants present with febrile illness at healthcare facilities; additional home visits may occur for vaccination status verification
Duration - Up to 21 days post-enrollment
Participants with confirmed iNTS infection and/or malaria infection are monitored for disease progression and outcomes, including hospitalization follow-up until discharge or death.
Weekly visits every 7 to 9 days until disease resolution, death, or 21 days post-enrollment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tonney S Nyirenda, Wilson L Mandala, Melita A Gordon...
https://pubmed.ncbi.nlm.nih.gov/29248635/Jong-Hoon Kim, Bieke Tack, Fabio Fiorino...
https://pubmed.ncbi.nlm.nih.gov/38485477/Ralf Krumkamp, Benno Kreuels, Nimako Sarpong...
https://pubmed.ncbi.nlm.nih.gov/26933027/James Church, Kathryn Maitland
https://pubmed.ncbi.nlm.nih.gov/24548672/John A Crump, Maria Sjölund-Karlsson, Melita A Gordon...
https://pubmed.ncbi.nlm.nih.gov/26180063/Vera von Kalckreuth, Frank Konings, Peter Aaby...
https://pubmed.ncbi.nlm.nih.gov/26933028/Se Eun Park, Gi Deok Pak, Peter Aaby...
https://pubmed.ncbi.nlm.nih.gov/26933016/Kristin Bornstein, Laura Hungerford, David Hartley...
https://pubmed.ncbi.nlm.nih.gov/28182657/Mehreen S Datoo, Alassane Dicko, Halidou Tinto...
https://pubmed.ncbi.nlm.nih.gov/38310910/Susanne van Santen, Quirijn de Mast, Dorine W Swinkels...
https://pubmed.ncbi.nlm.nih.gov/23601932/International Vaccine Institute
Lead Sponsor